Reports indicate George Tidmarsh, director of the FDA’s Center for Drug Evaluation and Research (CDER), has been placed on administrative leave amid internal controversies. The moves were reported across outlets and amplified concerns about leadership continuity at the agency that oversees novel drug approvals. Coverage notes Tidmarsh had previously raised concerns internally; the departures compound a year that included other high‑profile exits and public scrutiny of FDA decision‑making. Stakeholders are watching for interim leadership changes and potential impacts on ongoing reviews of high‑priority programs. Any sustained vacancy or leadership instability at CDER could alter timelines for high‑impact applications and reshape industry expectations around regulatory predictability.